Genprex to Participate at BIO Europe Spring 2026 [Yahoo! Finance]
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.) In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throughout the duration of the conference, Genprex executives will be available to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting with Genprex management during the conference, please request a meeting through the conference meeting portal or by contacting
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingPR Newswire
- Genprex to Participate at BIO Europe Spring 2026PR Newswire
- Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat CancerPR Newswire
- Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersPR Newswire
GNPX
Sec Filings
- 3/18/26 - Form 8-K
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- GNPX's page on the SEC website